/

Sociétés

NM

Non vérifié

NMD Pharma

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologiePublicité/Marketing/Médias/Communication

11 communiqués de presse

Voir tous les communiqués de presse

10/03/2026

Biotechnologie

Annonces Économiques

Publicité/Marketing/Médias/Communication

NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2

Source

Émetteur

1.00

0

11/02/2026

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Source

Émetteur

1.00

0

02/02/2026

Biotechnologie

Annonces Économiques

Publicité/Marketing/Médias/Communication

NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2

Source

Émetteur

1.00

0

02/09/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer

Source

Émetteur

1.00

0

12/05/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Relate

Source

Émetteur

1.00

0

24/03/2025

Biotechnologie

Annonces Économiques

NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model

Source

Émetteur

1.00

0

05/01/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease

Source

Émetteur

1.00

0

18/12/2024

Biotechnologie

Annonces Économiques

NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics

Source

Émetteur

1.00

0

17/12/2024

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology

Source

Émetteur

1.00

0

17/11/2024

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0